Effects of glucose-lowering agents on cardiorespiratory fitness

doi:10.4239/wjd.v9.i12.230

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6662)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

610

WORD

259

HTML

3651

Tables (1-5)

212

Sum=4732

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

934

Download

996

Sum=1930

Dec 15, 2018 (publication date) through Jul 19, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Dec 15, 2018; 9(12): 230-238
Published online Dec 15, 2018. doi: 10.4239/wjd.v9.i12.230

Table 4 Effects of sodium–glucose cotransporter 2 inihibitors on cardiorespiratory fitness in patients with type 2 diabetes

Ref.	Study design	Subjects	SGLT2 inhibitors dose	Results
Núñez et al[45], 2017	Before-after study	19 patients with type 2 diabetes and heart failure	Empagliflozin, 10 mg/d	VO_2peak↑, ventilatory efficiency during exercise↑, 6-minute walking distance↑, ↓antigen carbohydrate 125
		Age (median): 72 yr
		Sex: 14 men and 5 women
		BMI: 30.6 ± 5.5 kg/m²
		HbA1c: No description
Carbone et al[46], 2018	Before-after study	15 patients with type 2 diabetes and heart failure	Empagliflozin, 10 mg/d	VO_2peak↑ in patients using loop diuretics
		Age (median): 60 yr		VO_2peak↓ in patients without loop diuretics
		Sex: 7 men and 8 women
		BMI (median): 34 kg/m²
		HbA1c (median): 7.8%

SGLT2: Sodium–glucose cotransporter 2; BMI: Body mass index; HbA1c: Hemoglobin A1c; VO₂: Oxygen consumption.

Citation: Hamasaki H. Effects of glucose-lowering agents on cardiorespiratory fitness. World J Diabetes 2018; 9(12): 230-238
URL: https://www.wjgnet.com/1948-9358/full/v9/i12/230.htm
DOI: https://dx.doi.org/10.4239/wjd.v9.i12.230